Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has downgraded Bolt Biotherapeutics (NASDAQ:BOLT) from Outperform to Market Perform and lowered the price target from $3 to $1.
May 15, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Leerink Partners downgraded Bolt Biotherapeutics from Outperform to Market Perform and reduced the price target from $3 to $1.
The downgrade from Outperform to Market Perform and the significant reduction in the price target from $3 to $1 by Leerink Partners is likely to negatively impact investor sentiment and the stock price of Bolt Biotherapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100